![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Somahlution Reveals Positive Study Results Showing Efficacy of DuraGraft
Somahlution Reveals Positive Study Results Showing Efficacy of DuraGraft
![](https://www.fdanews.com/ext/resources/test/Device_Images5/SurgicalTools.gif?t=1475621996&width=430)
Somahlution’s DuraGraft vascular graft treatment significantly improves long-term outcomes in coronary artery bypass grafting (CABG) surgery, the company said at the European Association for Cardio-Thoracic Surgery (EACTS) annual meeting.
DuraGraft treatment for 2,436 patients who underwent CABG surgery has shown statistically significant lower risks for non-fatal myocardial infarction, repeat revascularization, and a composite of all major adverse cardiac events.
DuraGraft is currently not available in the U.S. market. — Cynthia Jessup
Upcoming Events
-
11Jul
-
18Jul
-
21Oct